News

Number of news items returned: 61 to 80 records of 435

"Carhood launches AUD 1.5m pre-IPO round ahead of 2Q19 listing - new CEO"

07 December 2018

(5639 views)

  "Carhood launches AUD 1.5m pre-IPO round ahead of 2Q19 listing - new CEO"   "Carhood, a private Melbourne-based Australian car sharing rental ...

Helio Lending - Unlocking Cryptocurrency, Australian First Launches into Market

06 December 2018

(6332 views)

  "Unlocking Cryptocurrency, Australian First Launches into Market   Helio Lending today boldly launched into the Australian cryptocurrency market. Helio Lending is the ...

Edge Powercutter to be launched at upcoming World of Concrete Trade Show - Guarda

06 December 2018

(5549 views)

  Edge Powercutter to be launched at upcoming World of Concrete Trade Show - Guarda   "Guarda is excited to be launching the ...

Director Briefing with John O'Shea from Helio Lending Pty Ltd

03 December 2018

(5758 views)

  Please click on the link below to read the Director Briefing. For more information about Helio, please click here.

Readers, Birthday, Introductions & News - Funding Strategies Connect November 2018

30 November 2018

(5669 views)

  Readers, Birthday, Introductions & News - Funding Strategies Connect November 2018   Dear Readers, With the festive season fast approaching, I welcome you ...

Podcast: Unlocking The Value of Cryptocurrency (ft. John O'Shea, Founder of Helio Lending)

30 November 2018

(5938 views)

  Podcast: Unlocking The Value of Cryptocurrency (ft. John O'Shea, Founder of Helio Lending)   Eden Exchanges spoke to John O’Shea, Founder of ...

"Helio Lending working on USD 50m cryptocurrency listing on NYSE in 2019 - MD"

29 November 2018

(5980 views)

  "Helio Lending working on USD 50m cryptocurrency listing on NYSE in 2019 - MD"   "Helio Lending, a private Melbourne-based Australian cryptocurrency ...

Helio Lending partners with Crypto Tax Australia

28 November 2018

(6208 views)

  Helio Lending partners with Crypto Tax Australia   Helio Lending today announced an exciting partnership with Crypto Tax Australia, allowing cryptocurrency ...

Qponics begins upgrade to pilot algae farm in Brisbane

27 November 2018

(6056 views)

  "Qponics begins upgrade to pilot algae farm in Brisbane   Site preparation (image above) commenced on 26 November to upgrade the existing ...

AgFutures Presentation

21 November 2018

(5884 views)

  AgriTech Commercialisation – An Investment Perspective   Our Managing Director, Dr Mark Rainbird, was the keynote speaker at the recent AgFutures Innovation ...

"Helio Lending secures CASHFLOW INVESTMENTS"

16 November 2018

(6577 views)

  "Helio Lending secures CASHFLOW INVESTMENTS   Helio Lending today announced the imminent acquisition of CASHFLOW INVESTMENTS PTY LTD helping to drive ...

"Qponics seeks AUD 7m (USD 5m) pre-IPO funding ahead of listing by mid-2019 – CEO"

16 November 2018

(5794 views)

  "Qponics seeks AUD 7m (USD 5m) pre-IPO funding ahead of listing by mid-2019 – CEO"   Qponics, a public unlisted Queensland-based Australian ...

Launching in 2019: EMF Performance Centre Nerang

12 November 2018

(10412 views)

  Launching in 2019: EMF Performance Centre Nerang   EMF co-founder Scott walks us through the Nerang facility to explain everything we can ...

BlueMount Capital Appointed as Corporate Advisor by Qponics Limited

09 November 2018

(6629 views)

  BlueMount Capital Appointed as Corporate Advisor by Qponics Limited   BlueMount Capital is pleased to advise that we have been appointed Corporate ...

LAUNCH OF CUTTING EDGE SOLUTION TO COMBAT TOXIC SILICA DUST- Craig Penty from Guarda Group Holdings

07 November 2018

(6368 views)

  LAUNCH OF CUTTING EDGE SOLUTION TO COMBAT TOXIC SILICA DUST - Craig Penty from Guarda Group Holdings   “The fight against death ...

"Fighting Silicosis With Product Innovation"

29 October 2018

(6732 views)

  "Fighting Silicosis With Product Innovation"   "There are increasing reports of chronic illness, including silicosis and even deaths of trades people in ...

Congratulations, News and Events - Funding Strategies Connect October 2018

29 October 2018

(6266 views)

Congratulations, News and Events - Funding Strategies Connect October 2018     Dear Reader, Welcome to the October 2018 edition of Funding Strategies Connect! We ...

EMF Opens Upper Coomera Location

24 October 2018

(7882 views)

    EMF Opens Upper Coomera Location "We opened our latest edition to the EMF Group in September being EMF Performance Centre Upper ...

Walker Capital Closes Round 2

18 October 2018

(7152 views)

    Walker Capital Closes Round 2 "On behalf of Walker Capital, I am excited to announce the completion of Round 2 of ...

Conference report: SuperReturn Asia 2018, Hong Kong

16 October 2018

(6796 views)

  Conference report: SuperReturn Asia 2018, Hong Kong     BlueMount Capital's Director, M&A, Flora Mok, attended the SuperReturn Asia Conference at the JW ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625